Related Experiment Video
Updated: Feb 3, 2026

Isolation and Enrichment of Human Adipose-derived Stromal Cells for Enhanced Osteogenesis
Published on: January 12, 2015
HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells Through Interaction with Its Natural Antisense Transcript
Bingzong Li1, Huiying Han2, Sha Song2
1Department of Haematology, The Second Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Abstract:
The characteristics of mesenchymal stromal cells (MSCs) which derived from multiple myeloma (MM) patients are typically impaired in osteogenic differentiation. However, the underlying molecular mechanisms need to be further investigated. lncRNAs are emerging as critical regulation molecules in oncogenic pathways. In this study, we identified that bioactive lncRNA HOXC-AS3, which is transcribed in opposite to HOXC10, was presented in MSCs derived from bone marrow (BM) of MM patients (MM-MSCs). HOXC-AS3 was able to interact with HOXC10 at the overlapping parts and this interaction increased HOXC10 stability, then promoted its expression, conferring osteogenesis repression to MM-MSCs. In mouse models, intravenously administered siHOXC-AS3 was proven to be effective in prevention of bone loss, sustained by both anticatabolic activities and bone-forming. These data showed that lncHOXC-AS3 was required for osteogenesis in BM-MSCs by enhancing HOXC10 expression. Our finding thus unveils a novel insight for the potential clinical significance of lncRNA HOXC-AS3 as a therapeutic target for bone disease in MM. Stem Cells 2019;37:247-256.
Insights
Long non-coding RNA HOXC-AS3 enhances HOXC10 expression, impairing osteogenic differentiation in mesenchymal stromal cells from multiple myeloma patients. Targeting HOXC-AS3 may treat bone loss in multiple myeloma.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Mesenchymal stromal cells (MSCs) from multiple myeloma (MM) patients exhibit impaired osteogenic differentiation.
- Long non-coding RNAs (lncRNAs) are implicated in oncogenic pathways and cellular regulation.
- The specific molecular mechanisms behind impaired osteogenesis in MM-MSCs require further elucidation.
Purpose of the Study:
- To investigate the role of lncRNA HOXC-AS3 in the osteogenic differentiation of bone marrow-derived MSCs (BM-MSCs) from MM patients.
- To elucidate the interaction between HOXC-AS3 and HOXC10 and its effect on osteogenesis.
- To evaluate the therapeutic potential of targeting HOXC-AS3 in MM-related bone loss.
Main Methods:
- Identification and characterization of HOXC-AS3 in MM-MSCs.
- Analysis of the interaction between HOXC-AS3 and HOXC10.
- Assessment of HOXC-AS3's impact on osteogenic differentiation in vitro.
- In vivo studies using mouse models with systemically administered siHOXC-AS3 to evaluate bone loss prevention.
Main Results:
- lncRNA HOXC-AS3 was identified in MM-MSCs and interacts with HOXC10, increasing its stability and expression.
- HOXC-AS3 overexpression repressed osteogenic differentiation in MM-MSCs.
- Intravenous administration of siHOXC-AS3 prevented bone loss in mouse models by promoting bone formation and reducing catabolism.
- HOXC-AS3 enhances HOXC10 expression, which is crucial for osteogenesis in BM-MSCs.
Conclusions:
- lncRNA HOXC-AS3 plays a critical role in regulating osteogenesis in BM-MSCs by upregulating HOXC10 expression.
- HOXC-AS3 contributes to impaired osteogenic differentiation in MM-MSCs.
- lncHOXC-AS3 represents a potential therapeutic target for treating bone diseases associated with multiple myeloma.
Related Concept Videos
Master Transcription Regulators
Master Transcription Regulators
Cooperative Binding of Transcription Regulators
Cooperative Binding of Transcription Regulators
Transcriptional Regulation: Riboswitches
Transcription Factors

